Q-omics provides the consensus-scored SNORA51 profile across patient tissues and cancer cell-line models. SNORA51 expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in LUSC. Among the 18 cancer types available for tumor–normal comparison, SNORA51 is differentially expressed in 7, with the highest sampling consensus in STAD. Additionally, SNORA51 RNA expression shows 11,727 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight LUSC, STAD, and UVM as cancer lineages where SNORA51 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SNORA51 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SNORA51 survival associations across molecular data types. SNORA51 RNA expression shows survival associations in the most cancer types (21). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SNORA51 RNA expression–survival associations across cancer types. High SNORA51 expression shows unfavorable associations in LUSC, BRCA, HNSC, THCA and UVM, but favorable associations in SKCM. The LUSC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .001). Together, the overview and detailed table identify LUSC as the clearest survival context for SNORA51 RNA expression.
This table summarizes SNORA51 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 7. The strongest signals are observed in STAD for RNA.
This table ranks reproducible tumor–normal expression differences for SNORA51. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SNORA51 shows lower tumor expression in THCA and higher tumor expression in STAD, ESCA, COAD, LUSC and CHOL. The STAD box plot shows higher SNORA51 RNA expression in tumor versus normal tissue (log2 FC = +0.565, t-test p < 0.001).
This table shows molecular features associated with SNORA51 in patient tissues and cancer cell lines. In patient samples, SNORA51 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set.
